X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

API PA by API PA
22nd July 2025
in FDA Approvals, News
FDA Accepts BLA for Recommended

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Bio-Thera Solutions announced that the FDA has accepted its Biologics License Application (BLA) for BAT2506, a proposed biosimilar to SimponiĀ® (golimumab).Ā  The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is 16th May 2026.

Bio-Thera’s US commercialization partner Accord BioPharma submitted the BLA and would be the MA holder if BAT2506 receives approval. Accord BioPharma filed the BLA with FDA on 16th May 2025.Ā  FDA accepts BLA requests approval for all approved presentations and all currently approved indications for Simponi, including:

1) Moderately to severely active rheumatoid arthritis (RA) in adults, used with methotrexate.

2) Active psoriatic arthritis (PsA) in adults, used alone or with methotrexate

3) Active ankylosing spondylitis (AS) in adults

4) Moderately to severely active ulcerative colitis (UC) in adults who reply on corticosteroids or haven’t responded well to or have undergone other treatments.

The BLA also requests BAT2506 be declared interchangeable with Simponi. Bio-Thera and Intas entered into a license and commercialization agreement for BAT2506 in February 2025. Bio-Thera will develop and manufacture the product in accordance with the terms of the agreement. Accord BioPharma, a U.S. specialty unit of Intas, will commercialize BAT2506 in the United States.

“The FDA’s acceptance of our BLA is a significant achievement that brings Bio-Thera closer to providing autoimmune patients in the USA with a high-quality, low-cost treatment option,” said Dr. Shengfeng Li, Founder and CEO of Bio-Thera Solutions. “Bio-Thera is committed to developing, manufacturing and commercializing biosimilars in the US and this marks the fourth FDA BLA that Bio-Thera has filed for a biosimilar.”

FDA accepts BLA submission as it is supported by a complete analytical, non-clinical, and clinical data package submitted to the FDA. Extensive analytical characterization between BAT2506 and US and EU SimponiĀ® was conducted on structural, physicochemical, and biological properties to support bio-similarity of BAT2506. A three-arm, single-dose, double-blind, randomized phase I study compared the pharmacokinetics, safety, and immunogenicity of BAT2506Ā® with both the US and EU SimponiĀ® in healthy volunteers.A randomized, double-blind, multicenter, parallel-arm, phase III study compared EU SimponiĀ® to BAT2506 for efficacy, safety, and immunogenicity in the patients with active psoriatic arthritis. The overall evidence proved that BAT2506 possesses similar efficacy, safety, immunogenicity, and quality as the reference product golimumab.

Previous Post

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

Next Post

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Aptar Pharma Bolsters Clinical Trial.

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

Ā© 2017 Copyright Ā© Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

Ā© 2017 Copyright Ā© Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In